Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Omeprazole and Famotidine on Cenicriviroc PK
NCT02684799Phase 1Completed
- Sponsor
- Tobira Therapeutics
- Start
- Jan 2016
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cenicriviroc in Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by Tobira Therapeutics. Primary endpoints: Maximum Plasma Concentration, Minimum Plasma Concentration and 1 more. Started Jan 2016; status: completed.
02
Drugs
cenicriviroc
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02684799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02684799.